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ABSTRACT
Background
There is currently limited experience on the feasibility and efficacy of autologous stem cell
transplantation in elderly patients with diffuse large B-cell lymphoma.
Design and Methods
We analyzed the outcome of 2612 patients with diffuse large B-cell lymphoma treated with
autologous stem cell transplantation between 2000 and 2005 and reported to the European
Blood and Marrow Transplantation registry. Four hundred and sixty-three patients (18%) were
≥60 years old at the time of the transplant (median, 63 years). When compared to 2149
patients <60 years old at the time of transplantation, the elderly patients had more frequently
received at least two treatment lines (76% vs. 57%, p<0.001), were less commonly in first com-
plete remission at the time of transplantation (23 % vs. 30 %, p=0.005) and received their
transplants later after diagnosis (median time 14 months vs.7.5 months, p<0.001).
Results
Non-relapse mortality was higher in elderly patients at 100 days (4.4 % vs. 2.8 %), at 1 year
(8.7% vs. 4.7%) and at 3 years (10.8% vs. 6.5%) (p=0.002). With a median follow-up of 12
months for the surviving patients for the elderly group and 15 months for the younger group,
the risk of relapse was 38% and 32%, respectively (p=0.006). The progression-free survival was
51% and 62%, respectively, at 3 years (p<0.001). The overall survival rate was 60% vs. 70%,
respectively, at 3 years (p<0.001).
Conclusions
Autologous stem cell transplantation is feasible in selected elderly patients with diffuse large
B-cell lymphoma, although non-relapse mortality is somewhat higher than in younger patients.
Both progression-free and overall survival rates are promising taking into account the general-
ly poorer outcome of elderly patients with diffuse large B-cell lymphoma.
Key words: autologous stem cell transplantation, diffuse large B-cell lymphoma, elderly
patients, non-relapse mortality, outcome.
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Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most
common type of non-Hodgkin’s lymphoma, account-
ing for 30-40% of all new cases. The median age of the
patients at diagnosis is more than 60 years. The propor-
tion of elderly patients is increasing in most societies
and consequently the number of DLBCL patients over
60 years of age is also continuously increasing.
Age over 60 years is a poor prognostic factor in the
International Prognostic Index. Recent improvements
in the management of DLBCL in elderly patients,
including addition of rituximab to CHOP1 and the use
of CHOP-14,2 have improved outcome in this most
common type of non-Hodgkin’s lymphoma. However,
a significant proportion of elderly patients with DLBCL
fail to achieve a complete remission or experience a
relapse associated with poor outcome.
High-dose chemotherapy supported by autologous
stem cell transplantation (ASCT) is a standard of care in
patients with relapsed chemosensitive aggressive lym-
phomas.3 The issue is more controversial in patients
receiving ASCT after the first-line treatment. Some
studies performed in the pre-rituximab era suggested
that ASCT is more beneficial than conventional thera-
py in patients with high-risk disease4-6 but most ran-
domized studies have not confirmed these observa-
tions.7-11
Limited data are available on the feasibility and effi-
cacy of ASCT in elderly patients with DLBCL. This is
due to the fact that the upper age limit in studies
including ASCT has been about 60 years and has only
recently been increased to 65 years. A general assump-
tion has been that ASCT is associated with higher tox-
icity and hence less clinical utility in elderly patients.
Current knowledge on the feasibility and efficacy of
ASCT in DLBCL patients 60 years or over is based on
several small reports.12-18 Only four series including at
least 20 transplanted DLBCL patients over 60 years of
age have been published.19-22 Although these reports
give some hints on early non-relapse mortality and out-
come, they are too small to facilitate proper analysis of
risk factors for non-relapse mortality or prognostic fac-
tors for long-term outcome. Therefore, a retrospective
analysis based on data in the European Blood and
Marrow Transplant (EBMT) registry was undertaken
by the Lymphoma Working Party.
Design and Methods
The EBMT is a voluntary organization comprising
525 transplant centers mainly from Europe. Member
centers are required to submit minimal essential data
(Med-A form) from consecutive patients to a central
lymphoma registry in which patients may be identified
by subtype of lymphoma and type of transplantation.
Participating transplant centers are subject to on-site
audits to assess data accuracy and consecutive report-
ing. Informed consent was obtained locally according
to regulations applicable at the time of transplantation.
Since January 1, 2003 all EBMT centers have been
required to obtain written informed consent prior to
data registration following the Helsinki Declaration of
1975.
The EBMT database was used to identify patients
with DLBCL aged 18-75 years old treated with a first
ASCT between 2000 and 2005. Altogether there were
6758 patients in the registry of whom 1327 (20 %)
were ≥60 years old at the time of transplantation. 
Only fully documented transplants with EBMT
MED-B forms (www.ebmt.org) were finally included in
the present study (n=2612). By multivariate analysis
this subgroup of patients was shown to be representa-
tive of all reported patients receiving ASCT for DLBCL
in the study period. 
Patients ≥60 years old at the time of transplantation
(n=463, 18%) were compared with younger patients
(n=2149) transplanted during the same period with
regards to non-relapse mortality and outcome. The
number of patients ≥60 years with DLBCL reported
increased from 172 in year 2000 to 265 in year 2005 (an
increase of 54% during the study period). The median
age of the elderly group of patients was 63 years (range,
60-74). Within this group of patients 311 (67%) were
60-64 years old, 139 patients (30%) 65-69 years old,
and only 13 patients (3%) 70-74 years old at the time of
ASCT. The median age of the younger group of
patients was 47 years old (range, 18-59).
Patient and transplant characteristics 
The characteristics of the patients and transplants of
the study population are presented in Table 1. Patients
transplanted at the age of 60 years or more less com-
monly had B-symptoms and bulky disease at the time
of diagnosis than had the younger patients. On the
other hand, the elderly patients received ASCT later,
had more often received at least two treatment lines
and were less commonly in first remission at the time
of transplantation. The median follow-up for the sur-
viving patients was 14.5 months. 
Statistical methods 
The main goal of this study was to investigate the
risk of non-relapse mortality and outcome after ASCT
in DLBCL patients 60 years or older, and compare these
with the risk of non-relapse mortality and outcome in
younger patients, while adjusting for significant
patient, disease- and transplant-related variables. All
the analyses were executed in the entire patient cohort,
considering age at ASCT (<60 years vs. ≥60 years) the
main study variable. 
Patient and transplant characteristics were compared
between groups using the χ2 test or Fisher’s exact test
for categorical variables and the t-test or Mann-
Whitney U-test for continuous variables. The probabil-
ities of progression-free survival were calculated from
the time of transplantation using the Kaplan-Meier
product-limit estimate, with the variance estimated by
Greenwood’s formula, and compared by the log-rank
test. Neutrophil engraftment, non-relapse mortality
and relapse or progression after ASCT were calculated
using cumulative incidences to account for competing
E. Jantunen et al.
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risks, and compared by Cox univariate analysis.
Potential prognostic factors for non-relapse mortality
were studied in multivariate analyses using Cox pro-
portional hazards regression. Some risk factors in the
Cox model contained a category for unknown to avoid
loss of information. The assumption of proportional
hazards for each factor in the Cox model was tested
using time-dependent covariates. All variables satisfied
the proportionality assumption. All variables were test-
ed for a significant interaction with the main factor
under study. All p values were two-sided. 
Cumulative incidences were calculated using the
NCSS 97 software. All other computations were per-
formed using the SPSS 13.0 statistical package.
Results
Table 1 presents the patients’ and transplant charac-
teristics according to age group. 
Hematologic engraftment
No differences were observed in the numbers of
CD34+ cells infused or in the use of growth factors
post-transplantation between the two groups. The
number of CD34+ cells infused was 5.2×106/kg (range,
0.6-47.2) in younger patients and 5.2×106/kg (range,
1.7-42.1) in patients over 60 years old. Granulocyte
colony-stimulating factor (G-CSF) was used in 61%
and 62% of the younger and older patients, respective-
ly. Among the elderly patients G-CSF was associated
with more rapid neutrophil engraftment (11 days vs. 13
days, p<0.001).
Neutrophil recovery occurred in all but 1.1% of
patients (0.9% in younger patients and 1.7% in patients
over 60 years of age at ASCT), with a median time to
reach an absolute neutrophil count above 0.5×109/L of
11 days in both groups. The cumulative incidence of
neutrophil engraftment was 99% (95% CI: 98.7-99.5)
in the younger patients and 98.3% (95% CI:97.1-99.5)
in the elderly patients (p=n.s.).
Non-relapse mortality 
The rate of non-relapse mortality was higher in the
group of elderly patients at all time points analyzed
(Figure 1). Non-relapse mortality in the elderly and
younger groups was 4.4% vs. 2.8% at 100 days after
ASCT, 8.7% vs. 4.7% at 1 year, and 10.8% vs. 6.5% at
3 years, respectively (p=0.002). No differences were
observed in non-relapse mortality at 100 days between
patients aged 60-64 and those aged 65-69 (4.4% vs.
4.2%). In multivariate analysis four factors were statis-
tically significantly associated with non-relapse mortal-
ity: age ≥ 60 years (RR 1.6, 95% CI 1.1.-2.3, p=0.01),
two or more lines of therapy prior to ASCT (RR
1.9,95% CI 1.3-2.8, p=0.001), poor performance status
at ASCT (RR 3.8, 95% CI 2.2-6.7, p=0.001), and refrac-
tory disease at ASCT (RR 1.9, 95% CI 1.1-3.3, p=0.02).
Infections were the main cause of non-relapse mor-
tality among the elderly patients (56%) followed by
multiorgan failure (16%), second malignancy (13%),
pulmonary toxicity (3%) and cardiac toxicity (3%).
Causes of death did not differ between younger and
elderly patients except for second malignancy, which
was more common in the elderly patients (13% vs.
5%). The risk of developing second malignancy was
2.5% vs. 1.4% at 3 years and 7.5% vs. 2.6% at 5 years,
respectively (RR 2.2, 95%CI 1.0-4.7, p=0.05). 
ASCT in elderly patients with DLBCL
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Table 1. Patient and transplant characteristics according to age at
the time of autologous stem cell transplantation.
<60 years ≥60 years p 
(n= 2149) (n=463)
Age, median (range), years 47 (18-59) 63 (60-74) −
Male sex 58.5% 59% n.s.
Stage III-IV 72% 71.5% n.s.
B-symptoms 49% 43% 0.04
Elevated LDH 49% 48% n.s.
Bulky disease 30% 19% <0.001 
Time from dx to tx, 7.5 14 <0.001
(median), months
Two or more previous 57% 76% <0.001
treatment lines
Prior rituximab therapy 26% 33% 0.009
Disease status/tx
CR1 30% 23% 0.005
CR ≥2/PR/sens rel 63% 71%
untested/refractory 7% 6%
Poor performance status at tx# 2.3% 3.7% n.s.
Stem cell source PB 99% 99% n.s.
TBI in conditioning 1.7% 1.1% n.s.
BEAM regimen 62% 73% <0.001
LDH: lactate dehydrogenase; n.s.: not significant; dx: diagnosis; tx: transplanta-
tion; CR: complete remission; PR: partial remission; sens: sensitive; rel: relapse;
#Karnofsky score; PB: peripheral blood; TBI: total body irradiation;
BEAM: carmustine-etoposide-cytarabine-melphalan. 
Figure 1. Non-relapse mortality according to age at the time of
autologous stem cell transplantation in patients with diffuse large
B-cell lymphoma. Solid line: patients ≥60 years old; dotted line:
patients <60 years old; p=0.002.
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Relapse risk
The cumulative risk of relapse at 3 years was 38% in
the elderly patients and 32% in the younger patients
(p=0.006) (Figure 2). In a multivariate analysis, four fac-
tors remained significant for the risk of relapse: no ritux-
imab therapy prior to ASCT (RR 1.6, 95% CI 1.3-2.0),
p<0.001), two or more lines of prior therapy (RR 1.7,
95% CI 1.4-2.0, p=0.001), poor performance status at
ASCT (RR 1.6, 95% CI 1.1.-2.5, p=0.02) and refractory
disease at ASCT (RR 2.8, 95% CI 2.1-3.7, p=0.001). On
the other hand, in a multivariate analysis, the elderly
patients showed only a trend towards a higher relapse
risk (RR 1.2, 95% CI 0.9-1.4, p=0.06).
Survival after autologous stem cell transplantation
The elderly patients had a lower progression-free sur-
vival rate than that of the younger patients (Figure 3).
The progression-free survival rate was 51% vs. 62% at
3 years, respectively (p<0.001). In a multivariate analy-
sis the following factors were associated with poorer
progression-free survival: age ≥60 years (RR 1.2, 95% CI
1.0-1.5, p=0.02), no rituximab therapy prior to ASCT
(RR 1.5, 95% CI 1.2-1.8, p<0.001), two or more lines of
therapy before ASCT (RR 1.6, 95% CI 1.4-2.0, p=0.001),
poor performance status (RR 2.1, 95% CI 1.5-2.9,
p=0.001), and refractory disease (RR 2.7, 95% CI 2.1-
3.5, p=0.001). Elderly patients who had had two or
more treatment lines prior to ASCT had a poorer pro-
gression-free survival than that of younger patients (RR
1.2, 95% CI 1.0-1.5, p=0.04). The impact of rituximab
therapy prior to ASCT was specifically analyzed as a
function of disease status at transplantation. Previous
rituximab use did not have any impact on the progres-
sion-free survival of patients autografted in first com-
plete remission. The absence of prior rituximab therapy
was, however, associated with poorer progression-free
survival in patiens transplanted in second complete
remission (p=0.03). 
The overall survival rate was inferior in the group of
elderly patients when compared to that in younger
patients (Figure 4). Overall survival was 60% vs. 70%,
respectively, at 3 years (p<0.001). In multivariate analy-
sis seven factors were associated with lower overall sur-
vival: male gender (RR 1.2, 95% CI 1-1.4, p=0.04), age
≥60 years (RR 1.4, 95% CI 1.2-1.7, p=0.001), no ritux-
imab therapy prior to ASCT (RR 1.5, 95% CI 1.2-1.9,
p<0.001), elevated serum lactate dehydrogenase level at
diagnosis (RR 1.3, 95% CI 1.1-1.6, p=0.008), two or
more lines of therapy prior to ASCT (RR 1.8, 95% CI
1.5-2.2, p=0.001), poor performance status at ASCT (RR
2.7, 95% CI 1.8-3.9, p=0.001) and refractory disease at
ASCT (RR 2.9, 95% CI 2.2-3.9, p=0.001). 
Discussion
This retrospective study based on data collected in the
EBMT registry considered more than 2600 transplanted
DLBCL patients with MED-B reports available. Notably
there were 463 patients ≥60 years old at the time of
transplantation, allowing some estimation of non-
relapse mortality and outcome in elderly patients with
E. Jantunen et al.
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Figure 2. Relapse risk after autologous stem cell transplantation
in patients with diffuse large B-cell lymphoma according to age at
transplant. Solid line patients ≥60 years old; dotted line <60 years
old.
Figure 3. Progression-free survival after autologous stem cell
transplantation in patients with diffuse large B-cell lymphoma
according to the age at transplant. Solid line patients ≥60 years;
dotted line <60 years old.
Figure 4. Overall survival after autologous stem cell transplanta-
tion in patients with diffuse large B-cell lymphoma according to
the age at the time of transplant. Solid line patients ≥60 years
old; dotted line: <60 years old. 
0 12 24 36 48 60
Months after ASCT
p=0.006
Re
la
ps
e 
or
 p
ro
gr
es
si
on
Pr
og
re
ss
io
n-
fre
e 
su
rv
iv
al
Ov
er
al
l s
ur
vi
va
l
1.00
0.80
0.60
0.40
0.20
0.00
1.00
0.80
0.60
0.40
0.20
0.00
p<0.001
0 12 24 36 48 60
Months after ASCT
0 12 24 36 48 60
Months after ASCT
p<0.001
1.00
0.80
0.60
0.40
0.20
0.00
©F
er
ra
ta
 S
to
rti
 F
ou
nd
at
ion
DLBCL. The main observations were a somewhat high-
er non-relapse mortality rate among the elderly patients
than among the younger ones, but a reasonable out-
come after ASCT. These observations are of impor-
tance, especially with regards to a generally poorer out-
come of elderly patients with DLBCL. 
The proportion of elderly DLBCL patients transplant-
ed increased during the study period. There may be
several reasons for this. Increasing experience with
ASCT in many centers might be one explanation as
might be improvements in transplant settings includ-
ing, for example, the use of blood progenitor cells and
better supportive care. In addition, the proportion of
elderly patients in the population is increasing and,
therefore, so too is the proportion of elderly DLBCL
patients in most affluent societies. Consequently, more
elderly and often otherwise fit patients are considered
for ASCT if they have poor initial features or relapse
after first-line therapy.
The rate of early non-relapse mortality, i.e. within 100
days of ASCT, among the elderly patients in this series
(4.4%) compares favorably with the rates in many ear-
lier smaller series in which a significant proportion of
the patients had DLBCL.19,20 A probable explanation is
that the present series includes only patients transplant-
ed more recently while previous studies have included
patients transplanted during a longer time period. Of
note, there was no statistically significant difference in
non-relapse mortality between patients aged 60-64 and
those aged 65-69 in our analysis. The number of
patients over 70 years old was too small for any mean-
ingful analysis. In general the causes of non-relapse
mortality were comparable in younger and older
patients, with infectious complications predominating.
The only major difference was in the risk of second
malignancies, which was higher in elderly patients. 
The follow-up of this registry analysis is relatively
short. However, taking into account that the median
time to relapse after ASCT in patients with DLBCL is
only 4 months,23 the observation time is sufficient to be
able to estimate the risk of relapse. With regards to
non-relapse mortality it is likely that the proportion of
cardiovascular deaths would increase in the elderly
patients and the relative proportion of infectious caus-
es would decrease with prolonged follow-up. The
same holds true with second malignancies, most of
which may have nothing to do with treatment of
DLBCL as such.
All transplanted patients are to some extent selected
based on either patient or disease-related characteristics
or both. It is likely that elderly patients are even more
selected than younger patients but this is impossible to
judge on the basis of a retrospective registry analysis. It
would be interesting to ask transplant centers whether
they have exactly the same inclusion and exclusion cri-
teria for older and younger patients with DLBCL. The
answers to this question could offer insight into the
patient selection process used in various centers and
give some basis for guidelines. Various co-morbidity
indices have been used in the allogeneic setting.24,25 Such
instruments might be useful also in elderly patients for
whom ASCT is contemplated.
In this registry series, elderly patients with DLBCL
had poorer progression-free and overall survival rates
than those of younger patients. This was in part due to
a higher risk of relapse and limited salvage options after
relapse but also due to higher non-relapse mortality.
Taking into account the facts that elderly patients had
more often received ASCT after at least two treatment
lines and were less often in the first complete remission
at the time of transplantation, the outcome of the elder-
ly population seems to be reasonable. 
Due to more common co-morbid conditions, elderly
patients tend to have more toxicities associated with
high-dose therapy. There may be ways to improve
this.26 In addition to patient selection, the conditioning
regimen also appears to be important. Regimens based
on total body irradiation have conventionally been used
cautiously in elderly patients, which was also apparent
in this registry analysis. BEAM was the most common-
ly used regimen both in elderly and younger patients. In
multivariate analysis of the present study, no differences
were observed in the outcomes according to the condi-
tioning regimen used. Routine use of G-CSF after stem
cell infusion might be advisable especially in elderly
patients. The combined use of radioimmunotherapy
together with high-dose chemotherapy and autologous
stem cell support might be one possibility to increase
the efficacy of the autologous procedure without
increasing early treatment-related toxicities.27
To conclude, ASCT is feasible in selected, elderly
patients with DLBCL although non-relapse mortality is
higher than in younger patients. The outcome seems to
be reasonable when considering the generally poorer
outcome of non-Hodgkin’s lymphomas in elderly
patients. More studies are needed to optimize patient
selection as well as to decrease early and long-term tox-
icity of ASCT. Age, as such, should no longer be consid-
ered a contraindication to ASCT in patients up to 70
years of age with non-Hodgkin’s lymphomas.
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